Primary Histiocytic Sarcoma of Parotid Gland: A Case Report and Review of Literature

Marwa T Hussien*
Department of Oncologic Pathology, South Egypt Cancer Institute, Assiut University, Egypt

Abstract

A case of female patient 55 years old, presented with painful right cheek mass, diagnosed as primary histiocytic sarcoma of parotid gland, immune confirmed. There is no lymph nodal involvement by lymphoma or metastatic disease at initial presentation.

Introduction

Histiocytic Sarcoma (HS) is a very rare neoplasm of hematopoietic origin. It accounts less than 1% of all malignancies of the hematopoietic system [1]. It formed of proliferation of malignant cells showing morphologic and immunophenotypic features similar to those of mature tissue histiocytes [2]. It can arise as a de novo primary malignancy or, less commonly, a secondary malignancy. There are multiple reports of presumed trans-differentiation from low-grade B-cell lymphoma to histiocytic sarcoma; this accounts for approximately one-fourth of cases [3]. The most frequent extranodal sites of histiocytic are the skin, spleen and gastrointestinal tract [4-6]. Histologically it is composed of a diffuse proliferation of large; round too void pleomorphic cells [7].

Materials and Methods

Clinical history

A 55 years old South Egyptian woman was admitted to the surgical oncology department at South Egypt Cancer Institute, Assiut University with a complaint of painful right cheek swelling. The medical and familial history was unremarkable.

Ultrasonography revealed ill-defined hyperechoic nodule in right parotid gland measured 8.5 cm × 6.5 cm. Contrast-enhanced axial CT image shows a solitary solid mass with ill-defined margins in the right parotid gland. The patient diagnosed as basaloid neoplasm by fine needle aspiration cytology.

At our institute, the patient underwent parotidectomy with safety margin. Postoperative CT pelvis revealed no residual lesion at tumor bed. Patient was referred to the medical oncology department. Metastatic work up was done and CT Chest revealed no metastatic deposits. Patient treatment plan was parotidectomy with safety margin.

Parotidectomy specimen was referred to our pathology department and dissected according to dataset guidelines of the Royal College of Pathologists.

Immunohistochemistry

Four-micron-thick sections were cut from the paraffin blocks, which were evaluated for immunohistochemistry. Immunostaining was performed using an automated staining machine (Dako Autostainer Link 48). The following primary antibodies were used: CK (AE1/AE3), LCA (CD 45), Vimentin, P63, S100, CD138 (M115), CD117, CD34, CD68, ki67 (MIB1) and P53. Markers were ready to use provided from Dako. Antigen retrieval was done in PT link using Dako system (Target Retrieval Solution, High pH, concentrated 50x Dako). Blocking of endogenous peroxidase activity was performed using Dako peroxidase blocking reagent. Slides were incubated with the primary antibody and then with a universal staining kit Horseradish Peroxidase (HRP). The slides were visualized with Diaminobenzidine (DAP solution) and subjected to haematoxylin counterstaining. Images and measurements were captured using Toup-Cam (XCAM Full HD Camera, model number: XCAM1080PHB).
Pathological findings

Results

Gross findings: Sections from the parotidectomy specimen showed an ill-defined large indurated tumor mass, replacing the normal parotid tissue. Serial sections showed heterogeneous grey white cut section with rubbery consistency, measuring 9 cm × 7 cm × 4.5 cm. It located 3 mm away from the surrounding labeled margins grossly.

Microscopic findings: Microscopically, the parotid tissue was diffusely infiltrated by sheets of large discohesive cells (Figure A). Tumor cells showed variable degree of pleomorphism, ample eosinophilic cytoplasm and large irregular nuclei. C: Tumor cells stained positively for both vimentin and D: CD68. E: Tumor cells were negative for CK; CK stained residual parotid acini (internal positive control). F: Tumor cells were negative for LCA, LCA stained tumor-infiltrating lymphocytes. G: Ki67 was high in reaching 40% in (hot spot). H: p53 strongly expressed in 50% of tumor cells.

Discussion

Histiocytic Sarcoma (HS) is an extremely rare malignant neoplasm showing morphologic and immunophenotypic evidence of histiocytic differentiation. The vast majority of previously reported histiocytic sarcomas are now generally recognized to be misdiagnosed examples of non-Hodgkin lymphomas, predominantly diffuse large B-cell lymphoma or anaplastic large cell lymphoma [8]. The extranodal histiocytic sarcomas were reported in head and neck [2], thyroid [9], duodenum and small intestine [6,10], colon [5,11], urinary bladder [12], spleen [4,13,14], leptomeninges [7,15].

Our discussion highlights a rare case of extranodal primary histiocytic sarcoma. We report a unique histiocytic sarcoma in parotid gland not associated with regional and non-regional lymph nodes histiocytic sarcoma or lymphoma. To our knowledge, this is second case of primary histiocytic sarcoma of parotid gland in literature. The first one diagnosed by Akiba et al. [16]. Our case was challenging and we set various differential diagnoses based upon the histopathologic morphology and excluded by immunohistochemistry. These differential diagnoses include undifferentiated carcinoma, lymphoma, myoepithelial carcinoma, myeloid sarcoma and lastly histiocytic sarcoma. The negativity for pancytokeratin exclude the undifferentiated carcinoma, the negativity for LCA (CD45) exclude lymphoma, the negativity for P63 and S100 exclude myoepithelial carcinoma, while negativity for both CD117 and CD34 exclude myeloid sarcoma. So, the only positivity for vimentin, CD68, P53 and Ki-67 that about 40%, confirm the diagnosis of histiocytic sarcoma.

Conclusion

Histiocytic sarcoma is a rare neoplasm. It must take in consideration in case with separate cells has abundant eosinophilic cytoplasm, with negative for epithelial lymphoid marker and positive for histiocytic marker.

References


